MedTrace Logo

Acute Liver Injury in Patients on Dapagliflozin

NCT02695095 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 424091

Last updated 2021-12-13

No results posted yet for this study

Summary

To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy.

Conditions

  • Acute Liver Injury

Sponsors & Collaborators

Principal Investigators

  • Catherine Johannes, Dr · RTI Health Solutions

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-09-01
Completion
2020-11-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02695095 on ClinicalTrials.gov